Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery.
about
Biotechnology: Crossing the barrierA monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeysSelective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein.IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey.Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein.Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor.IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys.AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys.Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey.Biopharmaceutical drug targeting to the brain.Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model.Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier.Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse.Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brainInsulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys.CHO cell expression, long-term stability, and primate pharmacokinetics and brain uptake of an IgG-paroxonase-1 fusion protein.Understanding barrier mechanisms in the developing brain to aid therapy for the dysfunctional brain
P2860
Q28291058-38E7B8C8-BFBB-48FD-909D-1BF27251FCEEQ28728201-EB5C268F-68F2-4607-BF4A-A4BE2D1EA338Q33703457-117317BF-335A-4431-96F1-CA193CA81E9EQ33726978-E224F0BB-DF5D-411D-A26E-37D7E2CADF95Q35079533-73F600F7-DAB5-4CBA-8CA3-F041538E6DB7Q36296187-44CA5984-646E-44ED-9B66-7614FC1156E7Q36546138-8C3F2F49-71E5-4C4F-81F3-ACFB5DF33CE0Q37440480-AABE4BDE-BD5B-488B-9256-7D3EF55CB239Q37444369-EE4AF54F-E839-408E-9A60-308910B914A8Q37671828-5A083943-A218-4425-B416-4B6EA3550BB2Q38703346-1E8E13AC-F2A7-4EDA-8DFB-01D032E16B10Q39685073-D733EF95-58C2-4DAE-A344-A4A328FCD2C2Q42089098-329298F0-9E08-4ED3-AFC8-A4E0C25BD209Q42591155-D3B91FA2-22FE-4425-9516-2B60D8704BE6Q42917594-913B65CB-EBFB-4C0A-94BF-115194D3C4E3Q46137409-640A800A-ECDF-42AA-BBD9-FE65B3EBADCFQ57199920-7E3D8D39-00A5-4E29-8943-54C9AC262D3A
P2860
Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics and safety in ...... blood-brain barrier delivery.
@en
Pharmacokinetics and safety in ...... blood-brain barrier delivery.
@nl
type
label
Pharmacokinetics and safety in ...... blood-brain barrier delivery.
@en
Pharmacokinetics and safety in ...... blood-brain barrier delivery.
@nl
prefLabel
Pharmacokinetics and safety in ...... blood-brain barrier delivery.
@en
Pharmacokinetics and safety in ...... blood-brain barrier delivery.
@nl
P2860
P1476
Pharmacokinetics and safety in ...... blood-brain barrier delivery.
@en
P2860
P304
P356
10.1007/S11095-009-9939-6
P577
2009-07-17T00:00:00Z